Connect
MJA
MJA

PACE: a specialised service for young people at risk of psychotic disorders

Alison R Yung, Patrick D McGorry, Shona M Francey, Barnaby Nelson, Kathryn Baker, Lisa J Phillips, Gregor Berger and G Paul Amminger
Med J Aust 2007; 187 (7): 43.
  • Alison R Yung1,2
  • Patrick D McGorry3,2
  • Shona M Francey1
  • Barnaby Nelson1
  • Kathryn Baker1
  • Lisa J Phillips1,3
  • Gregor Berger3,4
  • G Paul Amminger3,5

  • 1 PACE Clinic, ORYGEN Youth Health, Melbourne, VIC.
  • 2 ORYGEN Research Centre, University of Melbourne, Melbourne, VIC.
  • 3 University of Melbourne, Melbourne, VIC.
  • 4 University Hospital Basel, Basel, Switzerland.
  • 5 Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria.

Correspondence: aryung@unimelb.edu.au

Competing interests:

Alison Yung was involved as a researcher with a randomised controlled trial in the PACE Clinic that was partially funded by an educational grant from Janssen-Cilag. This grant was unrestricted and investigator initiated. Janssen-Cilag was not involved in any way in the study design, data collection, analysis and interpretation, writing or publication of this article. Alison Yung has also received travel assistance in the form of accommodation paid in part by Bristol-Meyer Squibb and Eli Lilly to attend conferences. Gregor Berger has served as consultant to, received honoraria from, and served as speaker at educational meetings for AstraZeneca, Eli Lilly and Janssen-Cilag.

  • 1. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 1996; 22: 353-370.
  • 2. Yung AR, McGorry PD, McFarlane CA, et al. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996; 22: 283-303.
  • 3. Hafner H, Maurer K, Trendler G, et al. Schizophrenia and depression: challenging the paradigm of two separate diseases — a controlled study of schizophrenia, depression and healthy controls. Schizophr Res 2005; 77: 11-24.
  • 4. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr Res 2003; 60: 21-32.
  • 5. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res 2004; 67: 131-142.
  • 6. Poulton R, Caspi A, Moffitt TE, et al. Children’s self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry 2000; 57: 1053-1058.
  • 7. Meares A. The diagnosis of prepsychotic schizophrenia. Lancet 1959; 1: 55-58.
  • 8. Sullivan HS. The onset of schizophrenia. 1927. Am J Psychiatry 1994; 151 (6 Suppl): 134-139.
  • 9. Pantelis C, Velakoulis D, McGorry P, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003; 361: 281-288.
  • 10. Corcoran C, Malaspina D, Hercher L. Prodromal interventions for schizophrenia vulnerability: the risks of being “at risk”. Schizophr Res 2005; 73: 173-184.
  • 11. Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodome: is it presently ethical? Schizophr Res 2001; 51: 31-38.
  • 12. McGorry PD, Yung A, Phillips L. Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr Res 2001; 51: 17-29.
  • 13. Yung AR, McGorry PD. Is pre-psychotic intervention realistic in schizophrenia and related disorders? Aust N Z J Psychiatry 1997; 31: 799-805.
  • 14. Bentall RP, Morrison AP. More harm than good: the case against using antipsychotic drugs to prevent severe mental illness. J Ment Health 2002; 11: 351-356.
  • 15. Tien AY. Distributions of hallucinations in the population. Soc Psychiatry Psychiatr Epidemiol 1991; 26: 287-292.
  • 16. van Os J, Hanssen M, Bijl RV, Vollebergh W. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban–rural comparison. Arch Gen Psychiatry 2001; 58: 663-668.
  • 17. Verdoux H, van Os J. Psychotic symptoms in non-clinical populations and the continuum of psychosis. Schizophr Res 2002; 54: 59-65.
  • 18. Johns LC, Cannon M, Singleton N, et al. Prevalence and correlates of self-reported psychotic symptoms in the British population. Br J Psychiatry 2004; 185: 298-305.
  • 19. Bell RQ. Multiple-risk cohorts and segmenting risk as solutions to the problem of false positives in risk for the major psychoses. Psychiatry 1992; 55: 370-381.
  • 20. Häfner H, Maurer K, Löffler W, Riecher-Rössler A. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993; 162: 80-86.
  • 21. Yung AR, Stanford C, Cosgrave E, et al. Testing the ultra high risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res 2006; 84: 57-66.
  • 22. Haroun N, Dunn L, Haroun A, Cadenhead K. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull 2006; 32: 166-178.
  • 23. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: review of studies. Acta Psychiatr Scand 2006; 113: 247-272.
  • 24. Yung AR, Phillips LJ, McGorry PD. Treating schizophrenia in the prodromal phase. London: Taylor and Francis, 2004.
  • 25. Phillips LJ, Yung AR, Hearn N, et al. Preventive mental health care: accessing the target population. Aust N Z J Psychiatry 1999; 33: 912-917.
  • 26. McGorry PD, Yung AR. Early intervention in psychosis: an overdue reform. Aust N Z J Psychiatry 2003; 37: 393-398.
  • 27. McGlashan TH. Psychosis treatment before psychosis onset: ethical issues. Schizophr Res 2001; 51: 47-54.
  • 28. Heinssen RK, Perkins DO, Appelbaum PS, Fenton WS. Informed consent in early psychosis research: National Institute of Mental Health Workshop, November 15, 2000. Schizophr Bull 2001; 27: 571-584.
  • 29. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59: 921-928.
  • 30. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163: 790-799.
  • 31. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004; 185: 291-297.
  • 32. Loewy RL, Bearden CE, Johnson JK, et al. The prodromal questionnaire (PQ): preliminary validation of a self-report screening measure for prodromal and psychotic syndromes. Schizophr Res 2005; 79: 117-125.
  • 33. Yung AR. The schizophrenia prodrome: a high risk concept. Schizophr Bull 2003; 29: 859-865.
  • 34. Yung AR, Yuen HP, Berger G, et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull 2007; 33: 673-681.
  • 35. McGorry PD, Hickie IB, Yung AR, et al. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006; 40: 616-622.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.